Selected inhibitors of protein tyrosine kinase activity
View Patent ↗The invention provides new compounds and compositions thereof. The invention also provides methods for treating ophthalmic diseases, disorders and conditions.
1. A compound selected from the group consisting of
and pharmaceutically acceptable salts, racemic and scalemic mixtures, diastereomers and enantiomers thereof.
2. The compound according to claim 1 , wherein the compound is
3. The compound according to claim 1 , wherein the compound is
4. The compound according to claim 1 , wherein the compound is
5. The compound according to claim 1 , wherein the compound is
6. The compound according to claim 1 , wherein the compound is
7. The compound according to claim 1 , wherein the compound is
8. The compound according to claim 1 , wherein the compound is
9. The compound according to claim 1 , wherein the compound is
10. The compound according to claim 1 , wherein the compound is
11. The compound according to claim 1 , wherein the compound is
12. The compound according to claim 1 , wherein the compound is
13. A composition comprising a compound according to any of claims 1 to 11 and a pharmaceutically acceptable carrier.
14. A method of inhibiting or relieving an ophthalmic disease, condition or disorder, the method comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to any of claims 1 to 12 or a composition thereof, wherein the ophthalmic disease, disorder or condition is selected from the group consisting of (a) a disease, disorder or condition caused by choroidal angiogenesis, (b) diabetic retinopathy and (c) retinal edema.
15. The method according to claim 14 , wherein the ophthalmic disease, disorder or condition is age-related macular degeneration.